Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial - Li Xu; Jinzhang Chen; Chang Liu; Xiaoling Song; Yanqiao Zhang; Haitao Zhao; Sheng Yan; Weidong Jia; Zheng Wu; Yabing Guo; Jiayin Yang; Wei Gong; et al. (BMC Medicine, 2024)